For many advanced practitioners, patients with hematologic malignancies may present infrequently due to the rarity of occurrence. The heterogenous presentation and clinical course of these diseases, along with the fast pace of scientific discovery, creates a challenging environment for clinicians to stay up to date on clinical management. This collection of presentations provides advanced practitioners with a comprehensive overview of treatment strategies and best practices for the side-effect management of novel therapies for various hematologic malignancies.
Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Error loading Partial View script (file: ~/Views/MacroPartials/JADPRO CE Faculty.cshtml)
Error loading Partial View script (file: ~/Views/MacroPartials/JADPRO CE Topic Items.cshtml)
These CME/CE/CPE certified activities are jointly provided by
 |
 |
 |
 |